• FirefoxInstall the new Firefox »
  •  Dow Up0.19% Nasdaq Up0.57%

    Alnylam Pharmaceuticals, Inc. (ALNY)

    -NasdaqGS
    104.06 Up 4.42(4.44%) Mar 27, 4:00PM EDT
    |After Hours : 104.08 Up 0.02 (0.02%) Mar 27, 5:57PM EDT
    Add to Portfolio
    Income StatementGet Income Statement for:
    View: Annual Data | Quarterly DataAll numbers in thousands
    Period EndingDec 31, 2014Sep 30, 2014Jun 30, 2014Mar 31, 2014
    Total Revenue 24,019   10,972   7,295   8,275  
    Cost of Revenue -   -   -   -  
    Gross Profit 24,019   10,972   7,295   8,275  
    Operating Expenses
    Research Development55,546  46,273  44,672  43,758  
    Selling General and Administrative14,185  9,898  11,518  8,925  
    Non Recurring -   -  (3,890)224,656  
    Others -   -   -   -  
    Total Operating Expenses -   -   -   -  
    Operating Income or Loss (45,712) (45,199) (45,005) (269,064)
    Income from Continuing Operations
    Total Other Income/Expenses Net2,232  1,277  616  251  
    Earnings Before Interest And Taxes(43,480)(43,922)(44,389)(268,813)
    Interest Expense -   -   -   -  
    Income Before Tax(43,480)(43,922)(44,389)(268,813)
    Income Tax Expense(22,091)67  (315)(17,870)
    Minority Interest -   -   -   -  
    Net Income From Continuing Ops(21,389)(43,989)(44,074)(250,943)
    Non-recurring Events
    Discontinued Operations -   -   -   -  
    Extraordinary Items -   -   -   -  
    Effect Of Accounting Changes -   -   -   -  
    Other Items -   -   -   -  
    Net Income (21,389) (43,989) (44,074) (250,943)
    Preferred Stock And Other Adjustments -   -   -   -  
    Net Income Applicable To Common Shares (21,389) (43,989) (44,074) (250,943)

    Sign Up for a Free Trial to EDGAR Online Premium!
    Get the critical business and financial information you need for more than 15,000 U.S. public companies.
    Sign Up Now - Learn More

    Currency in USD.